Mani A Daneshmand (@drmanictsurgery) 's Twitter Profile
Mani A Daneshmand

@drmanictsurgery

Director of Heart & Lung Transplant, MCS, & ECMO at Emory University. Tweets are my own views and not medical advice.

ID: 47885930

linkhttp://www.surgery.emory.edu/about-us/faculty_directory/faculty_profile_mani_daneshmand.html calendar_today17-06-2009 07:11:30

192 Tweet

1,1K Followers

556 Following

Duke Surgery (@dukesurgery) 's Twitter Profile Photo

John Haney, Assistant Professor of Surgery, will depart Duke as he becomes the next Chair of Cardiothoracic Surgery at Mayo Clinic Florida. We thank Dr. Haney for his lifelong (literally) dedication to Duke and wish him the best in this new opportunity! bit.ly/41Oidng

John Haney, Assistant Professor of Surgery, will depart Duke as he becomes the next Chair of Cardiothoracic Surgery at Mayo Clinic Florida.

We thank Dr. Haney for his lifelong (literally) dedication to Duke and wish him the best in this new opportunity! bit.ly/41Oidng
Aditi Nayak (@aditinayakmd) 's Twitter Profile Photo

🔥JACC Journals #JACCHF our commentary on WHY, WHEN and HOW to use #LVAD in #HF. @MRMehraMD Akshay Desai jacc.org/doi/10.1016/j.… WHY? Advanced #HF is defined by the transition from Neurohormonal➡️invasive LAPLACE therapeutics, for which #LVAD is the only scalable therapy 1/3

🔥<a href="/JACCJournals/">JACC Journals</a> #JACCHF our commentary on WHY, WHEN and HOW to use #LVAD in #HF. @MRMehraMD <a href="/akshaydesaimd/">Akshay Desai</a> 
jacc.org/doi/10.1016/j.…

WHY? 
Advanced #HF is defined by the transition from Neurohormonal➡️invasive LAPLACE therapeutics, for which #LVAD is the only scalable therapy
1/3
Aditi Nayak (@aditinayakmd) 's Twitter Profile Photo

2/3 WHY? Survival prognosis in the "Base Case" of Advanced #HF: 6 mo- 2 yrs depending on phenotype #LVAD provides "years to life and life to years" 👉 >5 years median survival gain 👪 👉 a sustained doubling of functional capacity and #QOL 🚶‍♀️💃

2/3 
WHY? 
Survival prognosis in the "Base Case" of Advanced #HF: 6 mo- 2 yrs depending on phenotype

#LVAD provides "years to life and life to years"
👉 &gt;5 years median survival gain 👪
👉 a sustained doubling of functional capacity and #QOL 🚶‍♀️💃
Aditi Nayak (@aditinayakmd) 's Twitter Profile Photo

3/3 WHEN to consider, HOW to COMMUNICATE to patients? 💡Use our Clinician's Aid (designed to be printed & used in primary care and cardiology clinics, ICUs, wards) 👉Personalized survival benefit estimate #HM3RS ➕ frailty,🍲 & psychosocial assmt helps shared decision making

3/3
WHEN to consider, HOW to COMMUNICATE to patients? 
💡Use our Clinician's Aid (designed to be printed &amp; used in primary care and cardiology clinics, ICUs, wards)
👉Personalized survival benefit estimate #HM3RS ➕ frailty,🍲 &amp; psychosocial assmt helps shared decision making
Neal Kumar Bhatia (@danealson) 's Twitter Profile Photo

Happy to share our work on mechanisms of VF in explanted human hearts. Thank you to Mani A Daneshmand for helping us with this endeavor. If you could also stop doing transplants at 3 AM, then I could get some sleep :-) tinyurl.com/2rbcbtfj Faisal Merchant Mikhael El-Chami

Happy to share our work on mechanisms of VF in explanted human hearts.  Thank you to <a href="/DrManiCTSurgery/">Mani A Daneshmand</a> for helping us with this endeavor.  If you could also stop doing transplants at 3 AM, then I could get some sleep :-)

tinyurl.com/2rbcbtfj

<a href="/FaisalMMerchant/">Faisal Merchant</a> <a href="/melchami99/">Mikhael El-Chami</a>
CA: A Cancer Journal for Clinicians (@cacancerjournal) 's Twitter Profile Photo

New #VirtualTumorBoard | Experts from Winship Cancer Institute of Emory University treat a young adult with metastatic #RenalCellCarcinoma and offer cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in this unique case. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… #TumorBoardTuesday #AACR24

New #VirtualTumorBoard | Experts from <a href="/WinshipAtEmory/">Winship Cancer Institute of Emory University</a> treat a young adult with metastatic #RenalCellCarcinoma and offer cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in this unique case.

acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

#TumorBoardTuesday
#AACR24
Joshua Chan, MD (@joshuachanmd) 's Twitter Profile Photo

First BrioVAD in the U.S. just done at Emory by Mani A Daneshmand! Exciting to see a new MagLev LVAD available for patients. news.emory.edu/stories/2024/1…

Emory Lung 🫁 Transplant (@emorylungtxp) 's Twitter Profile Photo

This month, we initiated a new Lung Transplant Consult Clinic at Emory Saint Joseph Hospital to enhance access for Georgia residents. #EmorySaintJosephHospital #LungTransplant #GeorgiaAccess

This month, we initiated a new Lung Transplant Consult Clinic at Emory Saint Joseph Hospital to enhance access for Georgia residents. #EmorySaintJosephHospital #LungTransplant #GeorgiaAccess
Joshua Chan, MD (@joshuachanmd) 's Twitter Profile Photo

ishlt.org/event-calendar… Joshua Preston is one of 5 finalist for the ISHLT Early Career Scientist Award - will be presenting our work on heart transplant PGD metabolomics!

Circulation (@circaha) 's Twitter Profile Photo

Clinical adaptation of Organ Care System (OCS) Heart device for DBD donors with a dedicated recovery team is associated with expanded donor criteria, longer transport distance and excellent post-transplant outcomes Josef Stehlik Yasuhiro Shudo @PARAGPATELMD ahajournals.org/doi/full/10.11…

Clinical adaptation of Organ Care System (OCS) Heart device for DBD donors with a dedicated recovery team is associated with expanded donor criteria, longer transport distance and excellent post-transplant outcomes <a href="/JosefStehlik/">Josef Stehlik</a> <a href="/yshudo1007/">Yasuhiro Shudo</a> @PARAGPATELMD ahajournals.org/doi/full/10.11…
Jacob Abraham, MD (@abraham_jacob) 's Twitter Profile Photo

Now out in Journal of Cardiac Failure: A prospective, multi-center registry of Impella 5.5 in HF-CS: 🔗bit.ly/4j8h171 🔑 Treatment with Impella 5.5 alone vs. multiple MCSD associated with ⬆️ survival and ⬇️complications 🔑 Patients bridged to HRT have 94% survival at 12- months

Now out in <a href="/JCardFail/">Journal of Cardiac Failure</a>: A prospective, multi-center registry of Impella 5.5 in HF-CS: 🔗bit.ly/4j8h171

🔑 Treatment with Impella 5.5 alone vs. multiple MCSD  associated with ⬆️ survival and ⬇️complications
🔑 Patients bridged to HRT have 94% survival at 12-
months